3 research outputs found

    a–c. Genotype distribution by year of reporting of acute HBV infections, the Netherlands, 2004–2010. a. Cases acquired heterosexually by men and women (n = 300); b. Cases with an unknown route of transmission acquired by men and women (n = 226) c. Cases acquired by men who have sex with men (n = 305).

    No full text
    <p>a–c. Genotype distribution by year of reporting of acute HBV infections, the Netherlands, 2004–2010. a. Cases acquired heterosexually by men and women (n = 300); b. Cases with an unknown route of transmission acquired by men and women (n = 226) c. Cases acquired by men who have sex with men (n = 305).</p

    Maximum parsimony tree based on the HBV S-region sequence of acute cases of HBV infection (n = 894), by most probable mode of transmission and gender, in the Netherlands, 2004–2010, and selected reference strains (n = 19).

    No full text
    <p>Maximum parsimony tree based on the HBV S-region sequence of acute cases of HBV infection (n = 894), by most probable mode of transmission and gender, in the Netherlands, 2004–2010, and selected reference strains (n = 19).</p

    Characteristics of the selective HBV vaccination programme for behavioural high-risk groups, The Netherlands, 1998–2010.

    No full text
    <p>Anti-HBc = antibody to the hepatitis B core antigen; CI = Confidence interval; HBsAg = hepatitis B surface antigen; STD = sexually transmitted disease.</p>†<p>Heterosexuals with frequent partner changes were no longer included in the programme from 2007 onwards.</p>‡<p>Proportion of the first vaccinations given at different locations, in percentages. Note: information about the vaccine location was missing for 3856 vaccinations.</p>§<p>Outreach locations included bars and saunas frequented by MSM, shelters for homeless people, and commercial sex worker locations.</p>¶<p>Prevalence was calculated by dividing the number of patients with a positive test by the total number with a test result.</p>∥<p>Compliance is defined as the proportion of those susceptible at the first vaccination completing three doses. Data up to 30 June 2011 were included.</p
    corecore